Kestra Medical Technologies reports developments as a commercial-stage wearable medical device and digital healthcare company focused on cardiovascular disease. Its updates center on the Cardiac Recovery System platform and the ASSURE WCD, a wearable cardioverter defibrillator used for patients at elevated risk of sudden cardiac arrest.
Recurring news includes fiscal results and revenue guidance, clinical data from the ASSURE WCD post-approval study, product and algorithm updates, healthcare conference presentations, and collaborations aimed at expanding diagnostic insight during cardiac recovery.
Biobeat Technologies has appointed Raymond W. Cohen as Chairman of the Board of Directors. The company, which develops wearable medical devices, has received FDA clearance for its innovative patch device that monitors multiple physiological parameters including continuous cuff-less ambulatory blood pressure.
Cohen brings over 40 years of life science industry experience, notably as co-founder and CEO of Axonics, which was acquired by Boston Scientific for $3.7 billion in 2024. Under his leadership, Axonics generated over $1 billion in revenue within four years of commercial launch. Most recently, as chairman of SoniVie, he led its sale to Boston Scientific for $600 million in March 2025.
Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has been awarded the 2025 Top Workplaces Industry Award by Energage. The recognition is based on employee feedback through an engagement survey, highlighting Kestra's commitment to maintaining a people-first workplace culture.
CEO Brian Webster emphasized that this achievement reflects the team's dedication to their mission of advancing cardiac care through employee empowerment. The award positions Kestra as an employer of choice in the healthcare sector, with the company's workplace culture being specifically recognized for its focus on employee voice and engagement.
Kestra Medical Technologies (NASDAQ:KMTS), a wearable medical device company, reported strong Q4 and FY2025 results. Q4 revenue reached $17.2 million, up 71% year-over-year, while FY25 revenue hit $59.8 million, a 115% increase from FY24. The company's ASSURE® cardiac recovery system saw 13,193 prescriptions in FY25, up 72% from the previous year.
Gross margins significantly improved to 44.3% in Q4 FY25 from 13.9% in the prior year, and 40.5% for FY25 compared to 1.3% in FY24. Despite growth, the company reported a GAAP net loss of $51.1 million in Q4 and $113.8 million for FY25. Looking ahead, Kestra projects FY26 revenue of $85 million, representing 42% growth.
[ "Revenue grew 115% year-over-year to $59.8 million in FY25", "Significant gross margin expansion to 40.5% in FY25 from 1.3% in FY24", "Strong prescription growth with 13,193 ASSURE® system prescriptions in FY25, up 72%", "Robust cash position of $237.6 million as of April 30, 2025", "Projected 42% revenue growth for FY26 with $85 million guidance" ]Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has scheduled its fourth quarter and fiscal year 2025 financial results announcement for Tuesday, July 15, 2025. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors can access both the live and archived webcast through the "Events" section of Kestra's investor relations website, with registration recommended at least 10 minutes before the call.
Kestra Medical Technologies (Nasdaq: KMTS), a company specializing in wearable medical devices and digital healthcare, has announced its participation in two major upcoming investor conferences.
The company will present at the following events:
- BofA Securities 2025 Health Care Conference on May 14 at 6:40 p.m. ET
- Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 11 at 8:00 a.m. ET
Investors and interested parties can access live webcasts and replays of both presentations through Kestra Medical Technologies' investor relations website.
Kestra Medical Technologies presented new real-world data for their ASSURE Wearable Cardioverter Defibrillator (WCD) at Heart Rhythm 2025 in San Diego. The study focused on outcomes in a community-based setting using an advanced practice provider (APP)-driven protocol.
Key findings demonstrate:
- High patient compliance with 23.3 hours median daily wear time
- Consistent usage beyond 90 days
- 4% of patients showed ventricular arrhythmias detection
- Successful implementation of APP-driven care model
- Effective continuity of care through ICD placement or hospitalization when needed
The study validates ASSURE's effectiveness in protecting patients from sudden cardiac arrest through both clinical performance and patient engagement. The results highlight the success of structured, team-based approaches in expanding access to cardiac care within community settings.
Kestra Medical Technologies (Nasdaq: KMTS) announced its participation in Heart Rhythm 2025, the annual Heart Rhythm Society meeting, scheduled for April 24-27 at the San Diego Convention Center. This marks the company's first major industry showcase following its recent IPO.
The company will showcase its ASSURE® system, a wearable medical device that combines defibrillation therapy with diagnostic and patient support capabilities. The exhibition will feature an immersive in-booth experience demonstrating the system's role in protecting patients at risk of sudden cardiac arrest.
During the event, Kestra will present new real-world clinical data about the ASSURE system's impact and continue its sponsorship of the Women in EP Luncheon for the fourth consecutive year.